{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:53:03Z","timestamp":1786978383787,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Rapid Comm Mass Spectrometry"],"published-print":{"date-parts":[[2024,1,30]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Pyrrolidone\u2010based drugs find widespread use in treating conditions such as epilepsy and Alzheimer's disease, and in various other medical applications. Brivaracetam, the latest generation of pyrrolidone drugs, has exhibited significant promise owing to chemical structure modifications. Its affinity to the SV2A receptor is double that of the previous\u2010generation drug, levetiracetam. Consequently, brivaracetam holds substantial potential for diverse applications. As a novel drug not yet included in the pharmacopeias of developed nations, comprehensive analysis and research are necessary to guarantee its safe utilization in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A liquid chromatography quadrupole time\u2010of\u2010flight tandem mass spectrometry (LC\/QTOFMS) method has been developed to effectively separate, identify and characterize both the degradation products and process\u2010related substances of brivaracetam. Stress testing of the sample was carried out following the guidelines outlined in ICH Q1A(R2). The structures of these impurities were identified through positive electrospray ionization QTOF high\u2010resolution MS and NMR spectroscopy. Additionally, the formation mechanism of each degradation product is thoroughly discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Under the analytical conditions outlined in this paper, brivaracetam and its degradation products were effectively separated. Thirteen degradation products were detected and characterized, shedding light on their origins and degradation pathways. Among these, three degradation products align with previously reported impurities, and two unreported degradation products were synthesized and confirmed through NMR spectroscopy. The stress testing results revealed the instability of brivaracetam under acidic, alkaline, oxidative and thermal stress conditions, while it exhibited relative stability under photolytic stress conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study developed an analytical method for brivaracetam that enabled the effective detection and separation of brivaracetam and its 13 degradation products. This method addresses a gap in both current domestic and foreign drug standards. The structures of all the major degradation products were characterized by high\u2010resolution LC\/QTOFMS, which is essential for quality control during the drug production process, stability evaluation and the establishment of proper storage conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/rcm.9651","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T18:47:13Z","timestamp":1700765233000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of degradation products of brivaracetam using liquid chromatography quadrupole time\u2010of\u2010flight tandem mass spectrometry: Degradation pathway elucidation"],"prefix":"10.1002","volume":"38","author":[{"given":"Kehui","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manru","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijuan","family":"Dong","sequence":"additional","affiliation":[{"name":"Public Laboratory Platform China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijun","family":"Hang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-0970","authenticated-orcid":false,"given":"Min","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis China Pharmaceutical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2015.0751"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535759719895280"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010017\u20108394\u20102"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892\u2010015\u20100588\u20103"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892\u2010015\u20100588\u20103"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2020.04.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)33064\u20108"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17253"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319230\u2010000000000\u201000000"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012944"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S114072"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13340"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010016\u20100376\u2010x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1631160"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2019.1615863"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARABJC.2013.04.016"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114297"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.5530\/223097131696"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2014.07.005"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmab137"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2016.1144201"},{"key":"e_1_2_7_24_1","unstructured":"HuangYM JianxiongY ZhiyongZ Changyue Inventor;Zhejiang Menovo Pharmaceutical Co. Ltd China assignee.Preparation of methyl (S)\u20102\u2010([R]\u20102\u2010oxo\u20104\u2010propylpyrrolidin\u20101\u2010yl)butanoate as Briviact impurity. US patent CN115557873."},{"key":"e_1_2_7_25_1","unstructured":"KavishwarG KumarA AdireddyD et al. Inventor;Neuland Pharma Research Private Limited India assignee.Process for the preparation of brivaracetam. US patent IN2018410131482019."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9an02145k"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.11665\/j.issn.1000\u20105048.20220509"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2022.101735"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/19440049.2018.1524157"},{"key":"e_1_2_7_30_1","unstructured":"International Conference on Harmonisation (ICH).Guideline Stability testing of new drug substances and products Q1A(R2) February 2003."},{"key":"e_1_2_7_31_1","volume-title":"USP 43\u2013NF 38","author":"United States Pharmacopeial Convention","year":"2020"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2020.131273"},{"key":"e_1_2_7_33_1","unstructured":"XiaCW Haixia Inventor; Hainan Xinkaiyuan Pharmaceutical Technology Co. Ltd China assignee.Preparation method of brivaracetam acid impurity by using (S)\u20102\u2010aminobutyrate hydrochloride. US patent CN1142133062022."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114764"}],"container-title":["Rapid Communications in Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.9651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T12:05:59Z","timestamp":1761480359000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/rcm.9651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,30]]}},"alternative-id":["10.1002\/rcm.9651"],"URL":"https:\/\/doi.org\/10.1002\/rcm.9651","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/RCM.9651\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/RCM.9651\/v1\/review2","asserted-by":"object"}]},"ISSN":["0951-4198","1097-0231"],"issn-type":[{"value":"0951-4198","type":"print"},{"value":"1097-0231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"2023-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e9651"}}